Premium
MINIMAL DOSE COMBINED HORMONAL REPLACEMENT THERAPY FOR MENOPAUSAL WOMEN
Author(s) -
Wren Barry G.
Publication year - 1981
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1981.tb135630.x
Subject(s) - progestogen , menopause , medicine , hormonal replacement therapy , hormone , incidence (geometry) , postmenopausal women , gynecology , hormonal therapy , hormone replacement therapy (female to male) , physiology , obstetrics , cancer , breast cancer , testosterone (patch) , physics , optics
The problem of managing postmenopausal women with hormonal replacement therapy is reviewed. A case is clearly made for using progestogen in every instance when women receive oestrogen in the menopause. By this means the incidence of carcinoma is reduced to at least the rate found in non‐treated patients and perhaps even lower. The biochemical changes leading to this reduction are summarized, and a suggestion is made regarding the optimal dosage of progestogen. This paper presents evidence to suggest that minimal doses of progestogen given for at least ten days in each month will protect endometrial target cells.